active ingredient semaglutide | C187H291N45O59 | CID 56843331 Semaglutide $99/mo Compounded (vs $1,349

Additional important safety considerations include: Risk of hypoglycaemia when combined with insulin or sulfonylureas Potential for dehydration and acute kidney injury from severe gastrointestinal symptoms Increased risk of diabetic retinopathy complications with rapid glucose lowering, particularly with semaglutide Importantly, memory loss or cognitive impairment is not listed among the recognised adverse effects in the Summary of Product Characteristics (SmPC) for any GLP-1 receptor agonist licensed in the UK

When diet and physical activity have not been successful, prescription medications such as semaglutide have shown promising results

However, its also prescribed off-label for weight loss support

Key Legal Precedents Related to Weight Loss Drug Injuries Wegovy lawsuits arent the first to challenge the pharmaceutical industry over weight loss medications

[Abstract] Representative WB images in different BV2 cell groups with Semaglutide (900 nM,20 h)